TY - JOUR
T1 - Haemophilus influenzae Infections Following Licensure of the Hib Vaccine
AU - Alexander, W. James
AU - Shaw, Joseph F.e.
AU - Holmes, J. Richard
AU - Osterholm, Michael T.
PY - 1987/7/16
Y1 - 1987/7/16
N2 - To the Editor: In April 1985, the Food and Drug Administration licensed the Haemophilus influenzae type b (Hib) vaccine for use in the United States, after a field trial had confirmed its efficacy.1 This vaccine, prepared from the capsular polysaccharide of the bacterium, has been envisioned as a cost-effective agent for reducing morbidity and mortality due to H. influenzae type b disease.2 Both the Immunization Practices Advisory Committee and the American Academy of Pediatrics have recommended universal vaccination for children 24 months of age.3,4 The U.S. Public Health Service has recommended that consideration be given to vaccinating children at high…
AB - To the Editor: In April 1985, the Food and Drug Administration licensed the Haemophilus influenzae type b (Hib) vaccine for use in the United States, after a field trial had confirmed its efficacy.1 This vaccine, prepared from the capsular polysaccharide of the bacterium, has been envisioned as a cost-effective agent for reducing morbidity and mortality due to H. influenzae type b disease.2 Both the Immunization Practices Advisory Committee and the American Academy of Pediatrics have recommended universal vaccination for children 24 months of age.3,4 The U.S. Public Health Service has recommended that consideration be given to vaccinating children at high…
UR - http://www.scopus.com/inward/record.url?scp=0023235569&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023235569&partnerID=8YFLogxK
U2 - 10.1056/NEJM198707163170311
DO - 10.1056/NEJM198707163170311
M3 - Letter
C2 - 3496536
AN - SCOPUS:0023235569
SN - 0028-4793
VL - 317
SP - 167
EP - 168
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 3
ER -
